Navigating Treatment Options after Triplet Therapy Failure in Prostate Cancer: Should a Second ARPI Be Considered?
/0 Comments/in Review/by MaxMetastasis-Directed Therapy: A Paradigm Shift in Metastatic Prostate Cancer Treatment
/0 Comments/in Review/by MaxPARP Inhibitors in Prostate Cancer: Navigating the Complexities of DNA Repair
/0 Comments/in Review/by MaxRadiotherapy in High-Burden Hormone-Sensitive Metastatic Prostate Cancer: Can It Be Useful?
/0 Comments/in Review/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare alphafold antibody-drug conjugate apalutamide artificial intelligence ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy cancer treatment castration-resistant prostate cancer chemotherapy clinical trial clinical trials crispr darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology oncology oncolytic virus personalized medicine prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- CRISPR is Here to Stay: Gene Therapy Succesfully Used On An Infant With Incurable Disease May 16, 2025
- Targeting the Undruggable: SCORT–Cas13d Nanotherapy Against Metastatic Prostate Cancer May 13, 2025
- Newsletter 19/2025 May 11, 2025
- UTRxM1-18: mRNA Drug Targeting c-MYC Offers New Hope for Prostate Cancer Patients May 10, 2025